The last 70 years have been transformational for the Indian biotech industry, mirroring the nation’s own rapidly advancing economy and rising global status. We have successfully leveraged recombinant DNA technology to deliver biopharmaceuticals, vaccines, genetically engineered crops and enzymes. In doing so, we have created a notable bio-economy valued at $35 billion. We have embraced … Continue reading India To Be A Biotech Hot Spot
Healing the World
To download the complete article, visit: http://bit.ly/2ncVkXM
Biocon Advances In War Against Diabetes
There are nearly half a billion diabetes patients in the world. The alarming growth in the global diabetes population is leading to a huge demand for effective therapies from pre/early diabetes to late-stage disease. Of the 100 million people who need insulin globally, however, only ‘one in two’ can manage and afford costs associated with … Continue reading Biocon Advances In War Against Diabetes
A Collaborative Approach to Healthcare Delivery
The highest attainable standard of health is a fundamental right of every human being. In this context, universal access to healthcare assumes prime importance. However, healthcare delivery poses a significant challenge for policymakers in India. A severe lack of resources means that there is only one doctor per 1,700 citizens in India, well below the … Continue reading A Collaborative Approach to Healthcare Delivery
Ensuring World Class Affordable Cancer Care
This video captures the highlights of the daylong NDTV Fortis CANCERTHON campaign telecasted on Sunday, Feb 8th, 2015. The initiative, focused on creating awareness on Cancer and raising funds to support treatment of children suffering with Cancer. This video talks about the affordable Cancer Care model at the Mazumdar Shaw Cancer Centre. Kiran Mazumdar Shaw … Continue reading Ensuring World Class Affordable Cancer Care
Why FY14 was a Remarkable Year for Biocon
The fiscal year gone by has been one of the most exciting ones for Biocon. We delivered on our promise of affordable innovation, recorded robust top line and bottom line growth, augmented our capacities, optimized our product portfolio and introduced initiatives to achieve operational efficiencies. We successfully commercialized two world-class, low-cost monoclonal antibodies, an outcome … Continue reading Why FY14 was a Remarkable Year for Biocon